WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2003072036) TREATMENT METHODS USING ANTI-CD22 ANTIBODIES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2003/072036    International Application No.:    PCT/US2003/005323
Publication Date: 04.09.2003 International Filing Date: 21.02.2003
IPC:
A61K 39/395 (2006.01), C07K 16/28 (2006.01)
Applicants: DUKE UNIVERSITY [US/US]; M454 Davison Building, DUMC Box 3664, Durham, NC 27710 (US) (For All Designated States Except US).
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; Office of the President, 1111 Franklin Street, Fifth Floor, Oakland, CA 94607 (US) (For All Designated States Except US).
TEDDER, Thomas [US/US]; (US) (For US Only).
TUSCANO, Joseph [US/US]; (US) (For US Only)
Inventors: TEDDER, Thomas; (US).
TUSCANO, Joseph; (US)
Agent: DREGER, Ginger, R.; Heller Ehrman, White & McAuliffe LLP, 275 Middlefield Road, Menlo Park, CA 94025-3506 (US)
Priority Data:
60/359,419 21.02.2002 US
60/420,472 21.10.2002 US
Title (EN) TREATMENT METHODS USING ANTI-CD22 ANTIBODIES
(FR) METHODES THERAPEUTIQUES UTILISANT DES ANTICORPS ANTI-CD22
Abstract: front page image
(EN)The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22).
(FR)L'invention concerne des méthodes thérapeutiques utilisant des anticorps monoclonaux anti-CD22 présentant des propriétés physiologiques uniques. L'invention concerne en particulier des méthodes de traitement des malignités des lymphocytes B. Ces méthodes consistent à administrer une quantité efficace d'un anticorps monoclonal bloquant anti-CD22, ledit anticorps se liant de manière spécifique aux deux premiers domaines Ig ou à un épitope à l'intérieur des deux premiers domaines Ig d'un CD22 humain natif (hCD22).
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)